Use of Nattokinase in patients with ischemic stroke and transient ischemic attacks
The concept of Nattokinase as an alternative to the standard prevention in acute ischemic cerebrovascular incidents is interesting and promising. Two groups of patients were considered – ones taking Nattokinase at a dose of 160 mg, 3000 fibrinolytic units of activity for 24 hours (n=96) and a control group, in which the secondary prevention was based on antithrombotic drugs – Acetylsalicylic acid (325/100 mg) and/or Clopidogrel (75 mg) daily (n=95). At a 6-month follow-up interval, no statistically significant difference was observed in the vascular (brain and cardiac) complications between the two categories monitored. The occurrence of adverse reactions in both groups was also statistically insignificant, in support of the reported literature and own initial data.